Similar Search Results

The Relationship between Ex Ante Mortality Risk and End-of-Life Medical Costs

Howard, David H.; Culler, Steven D.; Druss, Benjamin G.; … - In: Applied Health Economics and Health Policy 5 (2006) 1, pp. 37-44

-for-service Medicare beneficiaries, we document the association between mortality risk and end-of-life medical spending. Mortality risk at … found that, among decedents, end-of-life spending is inversely related to predicted mortality risk, ranging from $US23 …_000 for decedents with mortality risk in the interval 0.00-0.05 to $US16_000 for decedents with mortality risk >0.25 (1999 …

Persistent link: https://www.econbiz.de/10005404761

Handling Missing Data in Patient-Level Cost-Effectiveness Analysis alongside Randomised Clinical Trials

Manca, Andrea; Palmer, Stephen - In: Applied Health Economics and Health Policy 4 (2005) 2, pp. 65-75

Background: Missing data are potentially an extensive problem in cost-effectiveness analyses conducted alongside randomised clinical trials, where prospective collection of both resource use and health outcome information is required. There are several possible reasons for the presence of...

Persistent link: https://www.econbiz.de/10005404739

Comparison of Individual and Group Valuation of Health State Scenarios across Communities in West Africa

Akunne, Anayo Fidelis; Bridges, John F.P.; Sanon, Mamadou; … - In: Applied Health Economics and Health Policy 5 (2006) 4, pp. 261-268

Background: The correct valuation of health state scenarios is important for economic analyses, disease burden assessment and setting clinical guidelines. However, it is unclear whether we should use individual or group valuations. We aimed to compare individual and group valuations of a range...

Persistent link: https://www.econbiz.de/10005404740

The Economics of Prevention in a Post-Managed-Care Environment

Chang, Cyril F.; Waters, Teresa M.; Mirvis, David M. - In: Applied Health Economics and Health Policy 3 (2004) 2, pp. 67-70

Persistent link: https://www.econbiz.de/10005404741

Impact of Cross-Reference Pricing on Pharmaceutical Prices: Manufacturers' Pricing Strategies and Price Regulation

Stargardt, Tom; Schreyogg, Jonas - In: Applied Health Economics and Health Policy 5 (2006) 4, pp. 235-247

Objective: Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of foreign countries. Our objective is to quantify the theoretical cross-border spill-over effects of cross-reference pricing schemes on pharmaceutical prices in the former EU-15...

Persistent link: https://www.econbiz.de/10005404742

Observations on Health Financing Reform in the Republic of Georgia, 1996-2002

Schaapveld, Kees; Rhodes, Grant - In: Applied Health Economics and Health Policy 3 (2004) 3, pp. 127-132

Persistent link: https://www.econbiz.de/10005404743

Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density: How Do We Screen, Who Do We Screen and Who Do We Treat?

Schousboe, John T. - In: Applied Health Economics and Health Policy 6 (2008) 1, pp. 1-18

population and the costs of bone densitometry and drug treatment. The cost effectiveness of other technologies such as heel …

Persistent link: https://www.econbiz.de/10005404744

Methodological Aspects in the Assessment of Treatment Effects in Observational Health Outcomes Studies

Haro, Josep Maria; Kontodimas, Stathis; Negrin, Miguel Angel - In: Applied Health Economics and Health Policy 5 (2006) 1, pp. 11-25

Prospective observational studies, which provide information on the effectiveness of interventions in natural settings, may complement results from randomised clinical trials in the evaluation of health technologies. However, observational studies are subject to a number of potential...

Persistent link: https://www.econbiz.de/10005404745

Estimating Technical Efficiency in the Hospital Sector with Panel Data: A Comparison of Parametric and Non-Parametric Techniques

Siciliani, Luigi - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 99-116

Background: Policy makers are increasingly interested in developing performance indicators that measure hospital efficiency. These indicators may give the purchasers of health services an additional regulatory tool to contain health expenditure. Objective: Using panel data, this study compares...

Persistent link: https://www.econbiz.de/10005404746

Should We Maximise QALYs?: A Debate with Respect to Peak-End Evaluation

Oliver, Adam - In: Applied Health Economics and Health Policy 3 (2004) 2, pp. 61-66

Persistent link: https://www.econbiz.de/10005404747